Current treatment for prevention of relapse and recurrence in Crohn's disease

Citation
C. Prantera et Ml. Scribano, Current treatment for prevention of relapse and recurrence in Crohn's disease, ITAL J GAST, 31(6), 1999, pp. 515-518
Citations number
28
Categorie Soggetti
Gastroenerology and Hepatology
Journal title
ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
ISSN journal
11258055 → ACNP
Volume
31
Issue
6
Year of publication
1999
Pages
515 - 518
Database
ISI
SICI code
1125-8055(199908/09)31:6<515:CTFPOR>2.0.ZU;2-Q
Abstract
Maintenance of remission induced by medical therapy and prevention of recur rence after intestinal resection are two of the major goals in Crohn's dise ase treatment. Two main groups of drugs are employed in prevention of relap se and recurrence: sulfasalazine and 5-aminosalicylic derivatives and the g roup of azathioprine/6-mercaptopurine. Although most clinical trials on the efficacy of sulfasalazine as maintenance therapy of Crohn's disease have g iven negative results, it could probably be favourably used in remission ma intenance of Crohn's colitis. Controlled studies and two reviews have-shown that 5-aminosalicylic derivatives are effective in reducing the risk of re lapse. Ileitis and ileocolitis respond better than colitis. These drugs are also able to reduce the severity of lesions and of symptoms after surgery. 6-mercaptopurine and azathioprine can be used in more aggressive forms of the disease. The efficacy of this immunosuppressive therapy is reported in over 70% of patients and the incidence of associated side effects is accept able, but 6-mercaptopurine and azathioprine act slowly and the long latency period limits the usefulness of these drugs in some patients.